Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp

2026-Q1 EPS reported $0.52 revenue$132,865,000

YUTREPIA net product sales $129.9M in Q1 2026; over 4,500 prescriptions, ~3,750 patients treated since June 2025 launch.
Net income $52.9M ($0.60 basic, $0.52 diluted) vs net loss $38.4M ($0.45 loss) in Q1 2025 – third consecutive profitable quarter.
Adjusted EBITDA $71.2M; cash & equivalents $222.8M, up $32.1M from Q4 2025.
R&D expenses $12.6M (+$5.6M YoY) driven by L606 and YUTREPIA clinical programs.
Screening PH-ILD patients for Phase 4 Tyvaso transition study and pivotal Phase 3 Re-Spire study of L606.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Liquidia Corp reported first quarter ended March 31, 2026 results: revenue $129.9 million, net income $52.9 million, EPS $0.60 per basic and $0.52 per diluted share.

Period: first quarter ended March 31, 2026
Revenue: $129.9 million
Net income: $52.9 million
EPS: $0.60 per basic and $0.52 per diluted share
Result: reported results

Exact text from the filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-058234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.